Cantor Fitzgerald initiated coverage on DICE Therapeutics with a new price target
$DICE
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of DICE Therapeutics with a rating of Overweight and set a new price target of $36.00